01813nas a2200241   4500000000100000008004100001260001300042653002400055653001800079653003800097653001600135653001100151653001200162653002500174653002600199653001700225100001100242245010300253300001000356490000700366520118400373022001401557       1989                            d  c1989 Jun10aAntigens, Bacterial10aDisaccharides10aEnzyme-Linked Immunosorbent Assay10aGlycolipids10aHumans10aleprosy10aMycobacterium leprae10aSerum Albumin, Bovine10aTuberculosis1 aWu Q X00a[Studies on the serological activity of ND-O-BSA and its application in serodiagnosis of leprosy].  a220-40 v113 a<p>In this article, optimum conditions of ND-O-BSA-ELISA were determined and comparisons made of the serologic activity of 3 different types of antigens (WML, PGI, ND-O-BSA) in leprosy (151) and tuberculosis (20) patients and normal controls (42). The results indicated that: 1) optimum conditions for ND-O-BSA-ELISA were ND-O-BSA and OPD concentration of 0.1 and 400 micrograms/ml respectively with HRP-IgM and test sera dilutions of 1:1000 and 1:200; and 2) serological activity showed highly significant positive correlations between 3 types of antigens (WML vs PGI: r = 0.88, P less than 0.0005; PGI vs ND-O-BSA: r = 0.86, P less than 0.0005), all of which were highly sensitive and specific for leprosy serodiagnosis with positive rates of 100% (PGI) and 97.4% (WML, ND-O-BSA) in leprosy patients. None were positive in normal controls, but crossreactivity of different degree were present in tuberculosis patients. The authors suggest that PGI-ELISA and ND-O-BSA-ELISA be used in combination in the evaluation of clinical therapeutic efficacy and determination of disease stages, as well as in epidemiologic survey of subclinical leprosy infection in "high-risk" areas.</p>  a1000-503X